Novavax completes Nuvaxovid EU marketing authorization transfer to Sanofi; triggers $25M milestone

NOVAVAX INC

European Commission approved transfer of Nuvaxovid EU marketing authorization from Novavax CZ to Sanofi Winthrop Industrie.
Milestone payment of $25M triggered; Novavax expects receipt in Q1 2026.
Additional milestones: $25M for U.S. transfer, $75M for technology transfer, up to $350M for combo products.
Novavax eligible for tiered royalties on Sanofi's standalone COVID vaccine and combination products.
CEO John Jacobs: successful transfer is another step in ensuring global access to protein-based COVID vaccine.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.